Therefore, it is advisable to consider CMMRD also in genetically confirmed (mosaic) NF1 patients who have a malignancy that is not typical of NF1, such as a paediatric diffuse high-grade glioma, a T-cell lymphoblastic lymphoma or other. Here, NF1 is linked to neurofibromatosis type 1.